Catalog
Excipients are “inactive” ingredients that are added to therapeutic drug products that are not intended to exert therapeutic effects by themselves. However, these excipients may inhibit intestinal transporters that can be responsible for enhancing or reducing the absorption of not only the drug that is administered along with the excipient, but also the absorption of comedications that have never been tested with that excipient. Generic products may contain different excipients than the original branded medication, which may also contribute to unexpected drug-drug interactions.
Numerous excipients were tested and shown to inhibit OATP2B1, an intestinal drug uptake transporter, as well as BCRP and P gp, intestinal drug efflux transporters. Register for this informative webinar to hear expert insights and considerations on this topic.
About this item
Excipients are “inactive” ingredients that are added to therapeutic drug products that are not intended to exert therapeutic effects by themselves. However, these excipients may inhibit intestinal transporters that can be responsible for enhancing or reducing the absorption of not only the drug that is administered along with the excipient, but also the absorption of comedications that have never been tested with that excipient. Generic products may contain different excipients than the original branded medication, which may also contribute to unexpected drug-drug interactions.
Numerous excipients were tested and shown to inhibit OATP2B1, an intestinal drug uptake transporter, as well as BCRP and P gp, intestinal drug efflux transporters. Register for this informative webinar to hear expert insights and considerations on this topic.
Speaker Information
Mark Warren, Ph.D.
Dr. Mark S. Warren is Senior Director of Transporter Services at BioIVT and has more than 25 years’ experience in the drug transporter field.
He has been a contract research services study director since 2010, initially at Optivia Biotechnology, and then at BioIVT, when BioIVT acquired Optivia in 2018. In this role he has worked with clients to design and complete more than a thousand transporter studies for IND filings. Additionally, he collaborates with clients to determine how ADME and PK properties of investigational drugs are influenced by transporter mechanisms and optimizing those properties using SAR studies.
Previously, Mark worked at XenoPort, Inc., where his work on improving drug PK properties by modifying chemical structures to take advantage of active transport mechanisms led to several clinical candidates, including the FDA-approved gabapentin enacarbil. Mark also worked at Microcide Pharmaceuticals developing inhibitors of bacterial efflux transporters. Mark received his B.S. in Genetics from UC Davis, his M.S. in Chemistry and Ph.D. in Chemistry and Biochemistry from UC San Diego, and he completed postdoctoral work on enzyme reaction mechanisms at the Pennsylvania State University.